Hashimoto Koji, Inada Mika, Yamamoto Yusuke, Ochiya Takahiro
Corporate Research & Development Center, Toshiba Corporation, Kawasaki, Japan.
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute Japan, Tokyo, Japan.
Heliyon. 2021 Sep 2;7(9):e07919. doi: 10.1016/j.heliyon.2021.e07919. eCollection 2021 Sep.
Early detection and treatment are crucial for increasing the five-year survival rates of various cancers. Low-cost and convenient cancer screening tests are also critically important. Circulating microRNAs are reported as potential biomarkers for various cancers. Recently, miR-1307-3p was found to be a cancer-related microRNA. We evaluated the expression levels of miR-1307-3p in sera obtained from 254 patients with thirteen types of cancer (colon cancer, lung cancer, gastric cancer, liver cancer, bladder cancer esophageal cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, biliary tract cancer, brain cancer, sarcoma) and 27 non-cancer samples using isothermal amplification and microRNA chip. The expression levels of miR-1307-3p in sera obtained from cancer patients were clearly different from those obtained from non-cancer samples and differentiated the validation cohort into cancer patients and non-cancer control with high accuracy (AUC: 0.98; sensitivity: 0.98; specificity: 0.85). These results showed the potential relevance of miR-1307-3p in serum for the development of new diagnostic examination tools for cancer patients.
早期检测和治疗对于提高各种癌症的五年生存率至关重要。低成本且便捷的癌症筛查测试也极为重要。循环微RNA被报道为各种癌症的潜在生物标志物。最近，发现miR-1307-3p是一种与癌症相关的微RNA。我们使用等温扩增和微RNA芯片评估了从254例患有13种癌症（结肠癌、肺癌、胃癌、肝癌、膀胱癌、食管癌、乳腺癌、卵巢癌、前列腺癌、胰腺癌、胆管癌、脑癌、肉瘤）的患者以及27例非癌症样本中获取的血清中miR-1307-3p的表达水平。癌症患者血清中miR-1307-3p的表达水平与非癌症样本中的明显不同，并且能够以高精度将验证队列区分为癌症患者和非癌症对照（曲线下面积：0.98；灵敏度：0.98；特异性：0.85）。这些结果表明血清中的miR-1307-3p对于开发癌症患者新的诊断检查工具具有潜在相关性。
